RSS   Newsletter   Contact   Advertise with us

Immunomedics appoints Charles Baum to board

Share on Twitter Share on LinkedIn
Staff Writer | Morris Plains, N.J., USA |
ImmunomedicsImmunomedics, a biopharmaceutical company, announced that Charles Baum has joined the board of directors.
Dr. Baum is President, CEO and Board Member of Mirati Therapeutics since November 2012.

Prior to joining Mirati, Dr. Baum was Senior Vice President for Biotherapeutic Clinical Research at Pfizer and served as the Head of Oncology Development and as Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center.

Dr. Baum was responsible for the development of the oncology portfolio.

Previously, he was responsible for the development of several oncology compounds at Schering-Plough.

Dr. Baum currently serves on the Board of Array BioPharma.


 LATEST MOVES FROM New Jersey 


POST Online Media Contact